Anest. intenziv. Med. 2026;37(2):94-100 | DOI: 10.36290/aim.2026.012

Fungal cell wall antigens - the pitfalls in their interpretationReview Article

Müller J.1, 2, Valešová L.1, Raděj J.1, Kříž M.1, Horák J.1, 2, Huňková E.1, Pavlík R.1, Matějovič M.1, 2
1 Jednotka intenzivní péče, I. interní klinika, Fakultní nemocnice Plzeň
2 Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova

Micromycetes have emerged as a significant cause of opportunistic infection in immunocompromised and critically ill patients. The increasing utilisation of immune-modifying drugs has been accompanied by a rise in the incidence, morbidity and mortality of these life-threatening diseases. Beta-D-glucan and galactomannan, components of the fungal cell wall referred to as fungal antigens, can be detected in serum and other body fluids. Despite their well-established role in the diagnostic algorithm of fungal invasion, there are several major limitations associated with their evaluation. The accurate indication and interpretation of these non-culture diagnostic tests is imperative for the successful diagnosis and timely treatment of invasive fungal infections.

Keywords: beta­‑D-glucan, galactomannan, invasive fungal infections, candida, aspergillus, immunosuppression.

Received: February 10, 2026; Revised: April 7, 2026; Accepted: April 15, 2026; Prepublished online: June 8, 2026; Published: July 10, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Müller J, Valešová L, Raděj J, Kříž M, Horák J, Huňková E, et al.. Fungal cell wall antigens - the pitfalls in their interpretation. Anest. intenziv. Med. 2026;37(2):94-100. doi: 10.36290/aim.2026.012.
Download citation

References

  1. Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24(7):e428-38. doi: 10.1016/S1473-3099(23)00692-8. Go to original source... Go to PubMed...
  2. Bassetti M, Giacobbe DR, Agvald-Ohman C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S, et al. Invasive fungal diseases in adult patients in intensive care unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM. Intensive Care Med. 2024;50(4):502-15. doi: 10.1007/s00134-024-07341-7. Go to original source... Go to PubMed...
  3. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky-Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol. 2006;44(3):267-72. doi: 10.1080/13693780500474327. Go to original source...
  4. Theel ES, Jespersen DJ, Iqbal S, Bestrom JE, Rollins LO, Misner LJ, et al. Detection of (1, 3)-β-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2013;175(1-2):33-41. doi: 10.1007/s11046-012-9579-y. Go to original source... Go to PubMed...
  5. Rose SR, Vallabhajosyula S, Velez MG, Fedorko DP, VanRaden MJ, Gea-Banacloche JC, et al. The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections. J Infect. 2014;69(3):278-83. doi: 10.1016/j.jinf.2014.04.008. Go to original source... Go to PubMed...
  6. Forster J, Hoenigl M, Suerbaum S, Wagener J, Dichtl K. Serologic biomarkers in Candida and Aspergillus infections of the central nervous system: A comparison of galactomannan, mannan and β-1,3-D-gucan testing from serum and cerebrospinal fluid. Mycoses. 2022;65(7):709-14. doi: 10.1111/myc.13451. Go to original source... Go to PubMed...
  7. Novy E, Rivière J, Nguyen M, Arfeuille G, Louis G, Bouhemad B, et al. Combination of serum and peritoneal 1.3-beta-D-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study. Crit Care. 2023;27(1):470. doi: 10.1186/s13054-023-04761-7. Go to original source...
  8. He S, Hang J-P, Zhang L, Wang F, Zhang D-C, Gong F-H. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: Focus on cutoff levels. J Microbiol Immunol Infect. 2015;48(4):351-61. doi: 10.1016/j.jmii.2014.06.009. Go to original source...
  9. Ellis M, Al-Ramadi B, Finkelman M, Hedstrom U, Kristensen J, Ali-Zadeh H, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57(Pt 3):287-95. doi: 10.1099/jmm.0.47479-0. Go to original source... Go to PubMed...
  10. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55(4):521-6. doi: 10.1093/cid/cis456. Go to original source... Go to PubMed...
  11. White SK, Schmidt RL, Walker BS, Hanson KE. (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database Syst Rev. 2020;7(7):CD009833. doi: 10.1002/14651858.CD009833.pub2. Go to original source... Go to PubMed...
  12. White SK, Walker BS, Hanson KE, Schmidt RL. Diagnostic accuracy of β-d-glucan (Fungitell) testing among patients with hematologic malignancies or solid organ tumors: A systematic review and meta-analysis. Am J Clin Pathol. 2019;151(3):275-85. doi: 10.1093/ajcp/aqy135. Go to original source...
  13. Ullah N, Muccio M, Magnasco L, Sepulcri C, Giacobbe DR, Vena A, et al. Species-specific sensitivity and levels of beta-D-Glucan for the diagnosis of candidemia-A systematic review and meta-analysis. J Fungi (Basel). 2025;11(2):149. doi: 10.3390/jof11020149. Go to original source... Go to PubMed...
  14. Rouzé A, Estella Á, Timsit J-F. Is (1,3)-β-D-glucan useless to guide antifungal therapy in ICU? Intensive Care Med. 2022;48(7):930-2. doi: 10.1007/s00134-022-06766-2. Go to original source... Go to PubMed...
  15. Bloos F, Held J, Kluge S, Simon P, Kogelmann K, de Heer G, et al. (1→3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med. 2022;48(7):865-75. doi: 10.1007/s00134-022-06733-x. Go to original source... Go to PubMed...
  16. Cornely OA, Sprute R, Bassetti M, Chen SC-A, Groll AH, Kurzai O, et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2025;25(5):e280-93. doi: 10.1016/S1473-3099(24)00749-7. Go to original source...
  17. Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45(6):789-805. doi: 10.1007/s00134-019-05599-w. Go to original source... Go to PubMed...
  18. Kritikos A, Poissy J, Croxatto A, Bochud P-Y, Pagani J-L, Lamoth F. Impact of the beta-glucan test on management of intensive care unit patients at risk for invasive candidiasis. J Clin Microbiol. 2020;58(6). doi: 10.1128/jcm.01996-19. Go to original source... Go to PubMed...
  19. Leroy O, Bailly S, Gangneux J-P, Mira J-P, Devos P, Dupont H, et al. Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care. 2016;6(1):2. doi: 10.1186/s13613-015-0103-7. Go to original source... Go to PubMed...
  20. Furfaro E, Giacobbe DR, Del Bono V, Signori A, Guolo F, Minetto P, et al. Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies. Mycoses. 2018;61(9):650-5. doi: 10.1111/myc.12787. Go to original source...
  21. Lahmer T, Rasch S, Schnappauf C, Beitz A, Schmid RM, Huber W. Comparison of serum galactomannan and 1,3-beta-D-glucan determination for early detection of invasive pulmonary aspergillosis in critically ill patients with hematological malignancies and septic shock. Mycopathologia. 2016;181(7-8):505-11. doi: 10.1007/s11046-016-0011-x. Go to original source... Go to PubMed...
  22. Pazos C, Pontón J, Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005;43(1):299-305. doi: 10.1128/JCM.43.1.299-305.2005. Go to original source...
  23. Huang Q-Y, Li P-C, Yue J-R. Diagnostic performance of serum galactomannan and β-D-glucan for invasive aspergillosis in suspected patients: A meta-analysis. Medicine (Baltimore). 2024;103(5):e37067. doi: 10.1097/MD.0000000000037067. Go to original source... Go to PubMed...
  24. Kolbrink B, Scheikholeslami-Sabzewari J, Borzikowsky C, von Samson-Himmelstjerna FA, Ullmann AJ, Kunzendorf U, et al. Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany. Lancet Reg Health Eur. 2022;18(100400):100400. doi: 10.1016/j.lanepe.2022.100400. Go to original source... Go to PubMed...
  25. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5(4):298-308. doi: 10.1038/nrmicro1621. Go to original source...
  26. Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet A. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013;51(10):3380-8. doi: 10.1128/JCM.01554-13. Go to original source... Go to PubMed...
  27. Prosty C, Luo OD, Khalaf R, Del Corpo O, McDonald EG, Lee TC. Diagnostic test accuracy of the Fungitell serum (1→3)-β-D-glucan assay for the diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2025;31(4):542-50. doi: 10.1016/j.cmi.2024.11.004. Go to original source...
  28. Costa J-M, Botterel F, Cabaret O, Foulet F, Cordonnier C, Bretagne S. Association between circulating DNA, serum (1→3)-β-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia. Clin Infect Dis. 2012;55(2):e5-8. doi: 10.1093/cid/cis412. Go to original source... Go to PubMed...
  29. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140(5):1204-9. doi: 10.1164/ajrccm/140.5.1204. Go to original source... Go to PubMed...
  30. Damiani C, Demey B, Pauc C, Le Govic Y, Totet A. A negative (1,3)-β-D-glucan result alone is not sufficient to rule out a diagnosis of Pneumocystis pneumonia in patients with hematological malignancies. Front Microbiol. 2021;12:713265. doi: 10.3389/fmicb.2021.713265. Go to original source... Go to PubMed...
  31. Mikulska M, Ullah N, Magnasco L, Codda G, Bartalucci C, Miletich F, et al. Lower (1,3)-beta-d-glucan sensitivity and in vitro levels in Candida auris and Candida parapsilosis strains. Clin Microbiol Infect. 2024;30(6):822-7. doi: 10.1016/j.cmi.2024.02.012. Go to original source... Go to PubMed...
  32. León C, Ruiz-Santana S, Saavedra P, Castro C, Loza A, Zakariya I, et al. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care. 2016;20(1):149. doi: 10.1186/s13054-016-1324-3. Go to original source... Go to PubMed...
  33. Goudjil S, Chazal C, Moreau F, Leke A, Kongolo G, Chouaki T. Blood product transfusions are associated with an increase in serum (1-3)-beta-d-glucan in infants during the initial hospitalization in neonatal intensive care unit (NICU). J Matern Fetal Neonatal Med. 2017;30(8):933-7. doi: 10.1080/14767058.2016.1191064. Go to original source... Go to PubMed...
  34. Nagasawa K, Yano T, Kitabayashi G, Morimoto H, Yamada Y, Ohata A, et al. Experimental proof of contamination of blood components by (1→3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs. 2003;6(1):49-54. doi: 10.1007/s100470300008. Go to original source... Go to PubMed...
  35. Hammarström H, Kondori N, Friman V, Wennerås C. How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. Eur J Clin Microbiol Infect Dis. 2015;34(5):917-25. doi: 10.1007/s10096-014-2302-9. Go to original source... Go to PubMed...
  36. Duffner U, Abdel-Mageed A, Dahl K, Fogg G, Hester J. Serum (1→3)-β-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement. Bone Marrow Transplant. 2012;47(1):151-2. doi: 10.1038/bmt.2011.24. Go to original source... Go to PubMed...
  37. Liss B, Cornely OA, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-β-D-Glucan contamination of common antimicrobials. J Antimicrob Chemother. 2016;71(4):913-5. doi: 10.1093/jac/dkv419. Go to original source... Go to PubMed...
  38. Ito S, Ashizawa M, Sasaki R, Ikeda T, Toda Y, Mashima K, et al. False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G. J Infect Chemother. 2018;24(10):812-4. doi: 10.1016/j.jiac.2018.06.008. Go to original source...
  39. Mennink-Kersten MASH, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis. 2008;46(12):1930-1. doi: 10.1086/588563. Go to original source... Go to PubMed...
  40. Held J, Kohlberger I, Rappold E, Busse Grawitz A, Häcker G. Comparison of (1→3)-β-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol. 2013;51(4):1158-64. doi: 10.1128/JCM.02473-12. Go to original source... Go to PubMed...
  41. Albert O, Toubas D, Strady C, Cousson J, Delmas C, Vernet V, et al. Reactivity of (1→3)-β-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis. 2011;30(11):1453-60. doi: 10.1007/s10096-011-1244-8. Go to original source... Go to PubMed...
  42. Racil Z, Kocmanova I, Toskova M, Winterova J, Lengerova M, Timilsina S, et al. Reactivity of the 1,3-β-D-glucan assay during bacteraemia: limited evidence from a prospective study: 1,3-Β-D-glucan and bacteraemia. Mycoses. 2013;56(2):101-4. doi: 10.1111/j.1439-0507.2012.02210.x. Go to original source... Go to PubMed...
  43. Furfaro E, Mikulska M, Del Bono V, Guolo F, Minetto P, Gobbi M, et al. Bloodstream infections are an improbable cause of positive serum (1,3)-β-D-glucan in hematology patients. Clin Vaccine Immunol. 2014;21(9):1357-9. doi: 10.1128/CVI.00214-14. Go to original source... Go to PubMed...
  44. Sawai T, Nakao T, Yamaguchi S, Yoshioka S, Matsuo N, Suyama N, et al. Detection of high serum levels of β-D-Glucan in disseminated nocardial infection: a case report. BMC Infect Dis. 2017;17(1):272. doi: 10.1186/s12879-017-2370-4. Go to original source... Go to PubMed...
  45. Shah J, Dutta U, Rudramurthy S, Chakrabarti A, Sinha SK, Sharma V, et al. Colonic mucosa-associated candida assessed by biopsy culture is associated with disease severity in ulcerative colitis: A prospective study. J Dig Dis. 2019;20(12):642-8. doi: 10.1111/1751-2980.12825. Go to original source... Go to PubMed...
  46. Leelahavanichkul A, Worasilchai N, Wannalerdsakun S, Jutivorakool K, Somparn P, Issara-Amphorn J, et al. Gastrointestinal leakage detected by serum (1→3)-β-D-glucan in mouse models and a pilot study in patients with sepsis. Shock. 2016;46(5):506-18. doi: 10.1097/SHK.0000000000000645. Go to original source... Go to PubMed...
  47. Zhai B, Ola M, Rolling T, Tosini NL, Joshowitz S, Littmann ER, et al. High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nat Med. 2020;26(1):59-64. doi: 10.1038/s41591-019-0709-7. Go to original source... Go to PubMed...
  48. Samonis G, Kofteridis DP, Maraki S, Alegakis D, Mantadakis E, Papadakis JA, et al. Levofloxacin and moxifloxacin increase human gut colonization by Candida species. Antimicrob Agents Chemother. 2005;49(12):5189. doi: 10.1128/AAC.49.12.5189.2005. Go to original source... Go to PubMed...
  49. Yang A-M, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017;127(7):2829-41. doi: 10.1172/JCI90562. Go to original source... Go to PubMed...
  50. Szyszkowitz A, Zurl C, Herzeg A, Berger A, Gemes G, Mitteregger M, et al. Serum 1,3-beta-D-Glucan values during and after laparoscopic and open intestinal surgery. Open Forum Infect Dis. 2018;5(12):ofy296. doi: 10.1093/ofid/ofy296. Go to original source... Go to PubMed...
  51. Egger M, Horvath A, Prüller F, Fickert P, Finkelman M, Kriegl L, et al. Fungal translocation measured by serum 1,3-β-D-glucan correlates with severity and outcome of liver cirrhosis-A pilot study. Liver Int. 2023;43(9):1975-83. doi: 10.1111/liv.15648. Go to original source... Go to PubMed...
  52. Kanda H, Kubo K, Hamasaki K, Kanda Y, Nakao A, Kitamura T, et al. Influence of various hemodialysis membranes on the plasma (1→3)-beta-D-glucan level. Kidney Int. 2001;60(1):319-23. doi: 10.1046/j.1523-1755.2001.00802.x. Go to original source...
  53. Wong J, Zhang Y, Swift O, Finkelman M, Patidar A, Ramanarayanan S, et al. Beta-glucans in advanced CKD: role in endotoxaemia and inflammation. BMC Nephrol. 2020;21(1):118. doi: 10.1186/s12882-020-01779-9. Go to original source... Go to PubMed...
  54. Verweij PE, Weemaes CM, Curfs JH, Bretagne S, Meis JF. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol. 2000;38(10):3900-1. doi: 10.1128/JCM.38.10.3900-3901.2000. Go to original source...
  55. Leeflang MMG, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJPM, Hooft L, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015;2017(12):CD007394. doi: 10.1002/14651858.CD007394.pub2. Go to original source... Go to PubMed...
  56. Bassetti M, Azoulay E, Kullberg B-J, Ruhnke M, Shoham S, Vazquez J, et al. EORTC/MSGERC definitions of invasive fungal diseases: Summary of activities of the intensive care unit working group. Clin Infect Dis. 2021;72(Suppl 2):S121-7. doi: 10.1093/cid/ciaa1751. Go to original source... Go to PubMed...
  57. Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B, Fernández de Sevilla A, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59(12):1696-702. doi: 10.1093/cid/ciu673. Go to original source... Go to PubMed...
  58. Lai G, Zeng C, Mo J, Song W-D, Xu P. Diagnostic value of galactomannan in bronchoalveolar lavage fluid for chronic respiratory disease with pulmonary aspergillosis. J Clin Microbiol. 2020;58(3). doi: 10.1128/jcm.01308-19. Go to original source... Go to PubMed...
  59. de Heer K, Gerritsen MG, Visser CE, Leeflang MM. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2019;5(4):CD012399. doi: 10.1002/14651858.CD012399.pub2. Go to original source... Go to PubMed...
  60. Nuh A, Ramadan N, Shah A, Armstrong-James D. Sputum galactomannan has utility in the diagnosis of chronic pulmonary aspergillosis. J Fungi (Basel). 2022;8(2):188. doi: 10.3390/jof8020188. Go to original source... Go to PubMed...
  61. Chun JY, Jeong S-J, Kim S, Choi S, Lee JH, Chung HS, et al. Performance of the galactomannan test for the diagnosis of invasive pulmonary aspergillosis using non-invasive proximal airway samples. J Infect. 2024;88(6):106159. doi: 10.1016/j.jinf.2024.106159. Go to original source...
  62. Zandijk E, Mewis A, Magerman K, Cartuyvels R. False-positive results by the platelia Aspergillus galactomannan antigen test for patients treated with amoxicillin-clavulanate. Clin Vaccine Immunol. 2008;15(7):1132-3. doi: 10.1128/CVI.00022-08. Go to original source... Go to PubMed...
  63. Singh N, Obman A, Husain S, Aspinall S, Mietzner S, Stout JE. Reactivity of platelia Aspergillus galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother. 2004;48(6):1989-92. doi: 10.1128/AAC.48.6.1989-1992.2004. Go to original source... Go to PubMed...
  64. Boonsarngsuk V, Niyompattama A, Teosirimongkol C, Sriwanichrak K. False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis. 2010;42(6-7):461-8. doi: 10.3109/00365541003602064- Go to original source... Go to PubMed...
  65. Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, et al. Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother. 2012;67(7):1746-8. doi: 10.1093/jac/dks111. Go to original source... Go to PubMed...
  66. Penack O, Schwartz S, Thiel E, Wolfgang Blau I. Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam. Clin Infect Dis. 2004;39(9):1401-2; author reply 1402-3. doi: 10.1086/425131. Go to original source... Go to PubMed...
  67. Shin DW, Cho J, Choi KS, Lee J, Choi Y, Choi SJ, et al. False-positive results of galactomannan assays in patients administered glucose-containing solutions. Sci Rep. 2024;14(1):2552. doi: 10.1038/s41598-024-53116-x. Go to original source...
  68. Hage CA, Reynolds JM, Durkin M, Wheat LJ, Knox KS. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol. 2007;45(2):676-7. doi: 10.1128/JCM.01940-06. Go to original source... Go to PubMed...
  69. Van Der Veer J, Lewis RJ, Emtiazjoo AM, Allen SD, Wheat LJ, Hage CA. Cross-reactivity in the PlateliaTM Aspergillus enzyme immunoassay caused by blastomycosis. Med Mycol. 2012;50(4):396-8. doi: 10.3109/13693786.2011.608172. Go to original source...
  70. Wheat LJ, Hackett E, Durkin M, Connolly P, Petraitiene R, Walsh TJ, et al. Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol. 2007;14(5):638-40. doi: 10.1128/CVI.00479-06. Go to original source... Go to PubMed...
  71. Dalle F, Charles PE, Blanc K, Caillot D, Chavanet P, Dromer F, et al. Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan. J Clin Microbiol. 2005;43(6):2929-31. doi: 10.1128/JCM.43.6.2929-2931.2005. Go to original source... Go to PubMed...
  72. Aigner M, Wanner M, Kreidl P, Lass-Flörl C, Lackner M. Candida in the respiratory tract potentially triggers galactomannan positivity in nonhematological patients. Antimicrob Agents Chemother. 2019;63(6). doi: 10.1128/AAC.00138-19. Go to original source... Go to PubMed...
  73. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother. 2008;61(2):411-6. doi: 10.1093/jac/dkm463. Go to original source... Go to PubMed...
  74. Mennink-Kersten MASH, Ruegebrink D, Klont RR, Warris A, Gavini F, Op den Camp HJM, et al. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol. 2005;43(8):3925-31. doi: 10.1128/JCM.43.8.3925-3931.2005. Go to original source...
  75. Ansorg R, van den Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses. 1997;40(9-10):353-7. doi: 10.1111/j.1439-0507.1997.tb00249.x. Go to original source...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.